| 1 |
27181550 | Hepatitis B Virus Reactivation Following Salazosulfapyridine Monotherapy in a Patient with Rheumatoid Arthritis. | 2016 |
1 |
| 2 |
24394199 | Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. | 2014 Aug |
2 |
| 3 |
19560446 | Effects of NAT2 polymorphism on SASP pharmacokinetics in Chinese population. | 2009 Sep |
3 |
| 4 |
17377643 | N-acetyltransferase 2 slow acetylator genotype associated with adverse effects of sulphasalazine in the treatment of inflammatory bowel disease. | 2007 Mar |
1 |
| 5 |
15032315 | N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. | 2004 Feb |
1 |
| 6 |
12795783 | Sulphasalazine-induced leucopenia in a patient with renal dysfunction. | 2003 Jun |
1 |
| 7 |
12135032 | N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis. | 2002 Jul |
2 |
| 8 |
12186410 | N-acetyltransferase 2 genotype-related sulfapyridine acetylation and its adverse events. | 2002 Aug |
7 |
| 9 |
11604271 | Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine. | 2001 Oct 23 |
2 |
| 10 |
11642327 | N-Acetyltransferase 2 genotype correlates with sulfasalazine pharmacokinetics after multiple dosing in healthy Japanese subjects. | 2001 Oct |
5 |